Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

For your patients with pulmonary arterial hypertension (PAH, WHO Group I)

Actor portrayal Actor portrayals.

For your patients with pulmonary arterial hypertension (PAH, WHO Group I)

Actor portrayalActor portrayal

Treat early with UPTRAVI®1

Evidence-based ESC/ERS Guidelines recommend UPTRAVI® (selexipag) at first follow-up for intermediate–low-risk patients.2* Learn more »

Treat early with UPTRAVI®1

Evidence-based ESC/ERS Guidelines recommend UPTRAVI® (selexipag) at first follow-up for intermediate–low-risk patients.2* Learn more »

Consistent and validated 
efficacy1,3,4

The largest PAH pivotal trial that included a broad range of patients with diverse background therapies and etiologies

View GRIPHON Trial

10 years of established 
safety1,5

No new safety signals over 10 years

View 10-Year OLE

Convenient, oral BID dosing1,6†

In GRIPHON, UPTRAVI® was proven effective regardless of the patients' personal maintenance dose

View UPTRAVI® DOSING

Support programs and educational resources: 
Start patients on UPTRAVI®

DISCOVER NOW

*The 2022 ESC/ERS Guidelines recommend adding UPTRAVI® for patients without cardiopulmonary comorbidities who are at intermediate-low risk despite receiving ERA/PDE5i therapy. In these patients, switching from a PDE5i to riociguat may be considered. In patients who present as intermediate-high or high risk on oral therapies, also consider adding UPTRAVI® or switching from a PDE5i to riociguat if it is not feasible to add IV or SC prostacyclin analogs.2

†Once the patient's personal maintenance dose is achieved.

BID=twice daily; ERS=European Respiratory Society; ESC=European Society of Cardiology; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; OLE=open-label extension; WHO=World Health Organization.

References: 1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022‍;‍43‍(‍38‍)‍:‍3618‍-‍3731. 3. Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801908. doi:10.1183/13993003.01908-2018 4. Data on file. Actelion Pharmaceuticals US, Inc. Length and Population Size of PAH Pivotal Trials Confirmation. June 2024. 5. McLaughlin WV, Howard L, Elwing J, et al. 10-year data on oral selexipag: long-term survival, safety, and dosing insights in pulmonary arterial hypertension (PAH) from the GRIPHON study and its open-label extension (OLE). Oral presentation presented at: 2025 International Society for Heart & Lung Transplantation (ISHLT); April 27-30, 2025; Boston, MA. 6. Sitbon O, Channick R, Chin KM, et al; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-2533.